RA
INDV icon

Royce & Associates’s Indivior Pharmaceuticals INDV Stock Holding History

Royce & Associates’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$302K Sell
9,900
-297,957
-97% -$9.84M ﹤0.01% 740
2025
Q4 		$11M Buy
307,857
+61,333
+25% +$1.87M 0.11% 280
2025
Q3 		$5.94M Buy
+246,524
New +$5.16M 0.06% 436

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royce & Associates's INDV Position: Q1 2026 in Review

Royce & Associates reduced its Indivior Pharmaceuticals (INDV) stake by 97% in Q1 2026, selling an estimated $9.84M and leaving 9,900 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #740.

Royce & Associates first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. The position peaked at $11M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Royce & Associates held 9,900 shares of Indivior Pharmaceuticals worth $302K as of Q1 2026.
  • Royce & Associates sold 297,957 Indivior Pharmaceuticals shares in Q1 2026, an estimated $9.84M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Royce & Associates's portfolio in Q1 2026, its #740 holding.
  • Royce & Associates first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Royce & Associates's Indivior Pharmaceuticals position peaked at $11M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.